# Galmed Pharmaceuticals Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Galmed Pharmaceuticals Ltd.). ## Overview Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing Aramchol, a synthetic fatty acid-bile acid conjugate, for liver disease and oncology-related indications. The company is incorporated in Israel and operates through subsidiaries in Israel, Malta, and the United Kingdom, with its securities listed in the United States. ## Products & services • Aramchol clinical development program • GI and oncology drug candidate development • Preclinical and translational research • Specialty biopharmaceutical platform activities • Strategic licensing and acquisition of complementary assets - **Lead drug candidate development** (70%) — Development of Aramchol as a therapeutic candidate for liver disease and oncology indications. - **GI-focused oncology pipeline** (20%) — Research and development programs targeting gastrointestinal and GI-related oncology uses. - **Platform and IP assets** (10%) — Intellectual property, licensing, and development capabilities supporting future programs. - Aramchol clinical development program - GI and oncology drug candidate development - Preclinical and translational research - Specialty biopharmaceutical platform activities - Strategic licensing and acquisition of complementary assets ## Customers Galmed is primarily a development-stage biopharmaceutical company, so its direct “customers” are not end patients but rather future pharmaceutical partners, licensees, and potential commercial collaborators. Its programs are designed for healthcare providers and patients in liver disease, gastrointestinal disease, and oncology settings once a product reaches commercialization. - **Pharma licensing partners** (primary) — Buy or license clinical-stage assets such as Aramchol to expand their therapeutic pipelines. - **Future healthcare providers** (primary) — Would prescribe or administer Galmed’s therapies if approved for liver or GI oncology indications. - **Future patients** (primary) — Patients with liver disease or GI-related cancers who are the eventual end users of approved drugs. - **Research and development collaborators** (secondary) — Partners that support development programs, data generation, or clinical advancement. - Pharmaceutical partners seeking licensed clinical assets - Potential commercial collaborators for GI therapeutics - Healthcare providers treating liver disease patients - Oncology specialists treating GI-related cancers - Future patients who would use approved therapies ## Geography Galmed is incorporated in Israel and maintains subsidiaries in Malta, Israel, and the United Kingdom, while its securities trade in the United States. Its business footprint is therefore international even though the core operating and development structure is centered in Israel and adjacent jurisdictions. - Headquartered in Ramat Gan, Israel - Subsidiaries in Israel, Malta, and the United Kingdom - NASDAQ listing in the United States - Clinical development footprint is international by design - No country-level revenue disclosure was provided ## Strategy Galmed’s strategy centers on advancing Aramchol through development for GI and oncology indications and positioning the company as a specialty GI biopharmaceutical platform. The company also appears to be building capability through complementary transactions and partnerships that expand its therapeutic scope and potential commercialization options. - **Advance Aramchol through clinical development** (short-term) — Clinical progress is the main value driver for a development-stage biopharmaceutical company. - **Broaden into GI-related oncology** (medium-term) — A wider indication set can enlarge the addressable market and diversify pipeline risk. - **Develop a specialty GI platform** (medium-term) — A focused therapeutic platform can improve partnering leverage and strategic differentiation. - Advance Aramchol into later-stage development - Expand into GI-related oncology indications - Build a specialty GI biopharmaceutical platform - Pursue complementary assets through acquisitions - Use partnerships to support clinical and commercial path ## Risks Galmed faces the classic risks of a development-stage biotech company: clinical failure, regulatory setbacks, and the need to fund long development cycles before commercialization. The company also carries acquisition integration, IP, and going-concern style funding risk, which are especially important because its value depends on advancing a small number of programs successfully. - **Clinical development failure** [critical] — Aramchol is still under evaluation, so negative trial results could materially reduce pipeline value. - **Capital funding risk** [high] — The company states it will need substantial additional capital to fund operations and development. - **Regulatory approval risk** [high] — Drug candidates must clear safety and efficacy hurdles before commercialization. - **Intellectual property litigation** [medium] — The reports reference infringement, damages, royalties, and legal defense costs. - **Integration risk from acquisitions** [medium] — Acquired assets and businesses must be integrated without disrupting development plans. - Clinical trial failure could eliminate value for Aramchol - Regulatory approval risk remains high for all indications - Additional capital will be needed before commercialization - Acquisition and integration risk from complementary deals - Patent and litigation exposure can raise cost and delay programs ## Accounting As a development-stage biotech company, Galmed’s results are heavily affected by research and development expense recognition, stock-based equity issuance, and estimates tied to future funding and program success. The company also discloses going-concern language and uses cash-flow-based liquidity judgments, which are important because they influence how investors assess the durability of reported equity and the timing of future financing needs. - **Research and development expense recognition** — Directly affects operating loss and quarterly comparability - **Going-concern assessment** — Important for evaluating balance sheet and financing risk - **Pro forma acquisition accounting** — Can change the presentation of assets, liabilities, and future earnings base - **Shares outstanding and diluted EPS** — Affects reported per-share losses - R&D expense recognition drives reported losses - Going-concern assessment affects liquidity interpretation - Fair value and pro forma accounting may affect acquisitions - Equity issuance and share count change loss per share - Cash and restricted cash classification affects liquidity --- *Last updated: 2026-09-28T12:03:46.624987+00:00*